INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Weifang Guarantee Biological Technology Co. Ltd. researches, manufactures and wholesales vitro diagnostic products & medical equipment. The company was founded in 1996 and is headquartered in Weifang, China.

Shenzhen Haibo Biotechnology Co., Ltd., established on 2019-01-24, Business scope includes general business items:Reagent consumables related to biochemistry and environmental protection,cosmetic,Research and development, purchase and sale of experimental equipment;Research and development, purchase and sales of biological detection kits;Development of in vitro diagnostic reagents,Production and sales;Class I,Type II purchase and sales and biomedical technology development and scientific research technical services;Domestic trade and import and export business.(above laws,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:IIIPurchase and sale of similar medical device products;

The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.

Beijing Baotu Biotechnology Co., Ltd., established on 2021-04-02, Business scope includes technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Technical Services;software development;Basic software service;Application software service;Computer System Services;software service;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;product design;software consulting.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Beijing Xiangrui Biological Products Co., Ltd., established on 2000-03-24, Business scope includes production,Sales of small volume injections[vaccine(ACmeningococcal conjugate vaccine),In Vivo Diagnostic Reagents(Tuberculin pure protein derivative,BCG Pure Protein Derivatives)];Sales of Class III Medical Devices;Production of Class III medical devices(Production of in vitro diagnostic reagents);biotechnology development,consult,transfer;Import and export,Technology Import and Export,Agent import and export;SalesI,IIclass of medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of Class III medical devices(Production of in vitro diagnostic reagents)and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Hubei Nuomihua Antibody Drug Technology Co., Ltd., established on 2018-04-09, Business scope includes biopharmaceuticals,Class I medical device,Class II medical device,Class III medical devices,Research and development of chemical reagents,Production,Sales;Import and export.(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

Hebei Jingshuo Biotechnology Co., Ltd., established on 2016-12-19, The business scope includes clinical diagnostic reagents,Biochemical reagents,medical instruments,medical diagnosis,Monitoring equipment and treatment equipment,Veterinary and food safety testing reagents,Reagent testing equipment,genetically engineered organisms,microbial fermentation,cell culture,Antigen antibody technology research and development,Technical Services,Production,Sales;Own Equipment Rental;Chemical Products(Hazardous chemicals and precursor chemicals are excluded),Daily necessities,Wholesale and retail of plastic products;Biotechnology,Pharmaceutical technology research and development,technical consulting,Technical Services;Medical Supplies and Equipment,instrument,meter,Electronic Component,Chemical Reagents and Auxiliaries(Hazardous chemicals and precursor chemicals are excluded),Production of Drug Testing Instruments,Sales;Quality inspection technical service;Self-operation and agency of various commodities and import and export business,Except where restricted or prohibited by the country.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

IDEC Pharmaceuticals develop therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases. Idec Pharmaceuticals was founded in 1986 by UC-San Diego physician and immunologist Ivor Royston, San Diego bioentrepreneur Howard Birndorf, and Stanford University cancer researchers Ron Levy and Richard Miller. In 2003, Idec Pharmaceuticals was merged with Biogen.